TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36396375

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: cT3 stage
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Stage IV cancer
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Permanent stoma
Number of subjects: 331
Study: 33714594

Group type: EXPERIMENTAL
Intervention: 25(OH)D levels of 30 ng/mL and higher
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 25(OH)D as a continuous variable
Number of subjects: 144
Study: 35833120

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis MH‐02, 2 × 10^9 colony‐forming units per packet, once daily for 7 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis MH‐02
Number of subjects: 100
Study: 34663673

Group type: EXPERIMENTAL
Intervention: Alberta Family Integrated Care (AB‐FICare)
Number of subjects: 32
Study: 32649493

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 7 days after 3 consecutive days of bleeding or spotting
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 35294944

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 159

Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 159
Study: 35671033

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Metformin with comorbidity
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Metformin without comorbidity
Number of subjects: 502
Study: 32289804

Group type: EXPERIMENTAL
Intervention: Single motivational lecture (2 hours)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 145
Study: 36261822

Group type: EXPERIMENTAL
Intervention: Free scapular flap with CAD/CAM customized osteotomy guide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Free scapular flap without CAD/CAM customized osteotomy guide
Number of subjects: 22
Study: 33508239

Group type: EXPERIMENTAL
Intervention: Graft-less sinus lift (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cerabone as bone substitute (group 2)
Number of subjects: 20
Study: 32429983

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention targeting both professionals and patients to improve DRS uptake, including audit/feedback, electronic prompts for professionals, HCP-endorsed reminders (face-to-face, by phone, and letter), and an information leaflet for patients.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Core intervention components based on APEASE criteria.
Number of subjects: 47
Study: 35442175

Group type: EXPERIMENTAL
Intervention: Priming
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PrimingCaf
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study: 33400851

Group type: EXPERIMENTAL
Intervention: Downhill group (DG; n=7; downhill interval running at −10% incline)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Uphill group (UG; n=7; uphill interval running at +10% incline)
Number of subjects: 14
Study: 35135481

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34171466

Group type: EXPERIMENTAL
Intervention: US-ESP block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (opioid-based multimodal analgesia)
Number of subjects: 100
Study: 32302798

Group type: EXPERIMENTAL
Intervention: Patients with dementia undergoing oral and maxillofacial surgery
Number of subjects: 2420

Group type: EXPERIMENTAL
Intervention: Patients undergoing other than dentoalveolar surgery with dementia
Number of subjects: 2420

Group type: EXPERIMENTAL
Intervention: Patients undergoing dentoalveolar surgery
Number of subjects: 2420

Group type: EXPERIMENTAL
Intervention: Younger age in patients undergoing dentoalveolar surgery
Number of subjects: 2420

Group type: EXPERIMENTAL
Intervention: Higher anesthesiological risk in patients undergoing dentoalveolar surgery
Number of subjects: 2420
Study: 35244704

Group type: EXPERIMENTAL
Intervention: Varenicline tartrate, 1.0 mg, twice daily for 12 weeks and nicotine patch at manufacturer‐recommended doses for 10 weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo and nicotine patch
Number of subjects: 122
Study: 33979229

Group type: COMPARATOR
Intervention: Standard care (SOC)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Standard care plus topical oxygen therapy (SOC plus TOT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Standard care (SOC) and Standard care plus topical oxygen therapy (SOC plus TOT)
Number of subjects: 145
Study: 33879529

Group type: EXPERIMENTAL
Intervention: Microcuff cuffed ETT
Number of subjects: 76

Group type: COMPARATOR
Intervention: Portex uncuffed ETT
Number of subjects: 76
Study: 32065309

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 38
Study: 35818036

Group type: EXPERIMENTAL
Intervention: Verbal instruction group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Photo instruction group (immediate education)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Educational video group (immediate education)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Photo instruction group (advance education)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Educational video group (advance education)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Verbal instruction group (immediate education)
Number of subjects: 90
Study: 33077259

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 446

Group type: COMPARATOR
Intervention: High-grade serous (HGS) OC
Number of subjects: 446

Group type: COMPARATOR
Intervention: IA/IB/IC1 high-grade serous ovarian cancer (HGSOC)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Clear cell (CC) OC
Number of subjects: 446
Study: 33283468

Group type: EXPERIMENTAL
Intervention: Arginine dentifrice
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CSPS dentifrice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoride dentifrice (control)
Number of subjects: 60
Study: 32962724

Group type: EXPERIMENTAL
Intervention: FAM
Number of subjects: 41

Group type: COMPARATOR
Intervention: PED
Number of subjects: 41

Group type: COMPARATOR
Intervention: CON
Number of subjects: 41
Study: 35727655

Group type: EXPERIMENTAL
Intervention: Autospreader flap
Number of subjects: 48

Group type: COMPARATOR
Intervention: Spreader graft
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 34319971

Group type: EXPERIMENTAL
Intervention: Early assessment and intervention by a health and social care professional team (HSCP) in the ED
Number of subjects: 353

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 353
Study: 32497234

Group type: EXPERIMENTAL
Intervention: Adaptive Learning (AL) platform
Number of subjects: 23

Group type: COMPARATOR
Intervention: Traditional Learning Management System (LMS)
Number of subjects: 23
Study: 35041442

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control: Episodic Recent Thinking (ERT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EFT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall satisfaction across groups
Number of subjects: 52
Study: 32770640

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg with a loading dose (LD group)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg without a loading dose (NL group)
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 35333218

Group type: EXPERIMENTAL
Intervention: 8-week strength and flexibility program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 33121346

Group type: EXPERIMENTAL
Intervention: mRNA‐1777 (V171) 25, 100, 200, or 300 µg
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: mRNA‐1777 (V171)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 32418886

Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice daily
Number of subjects: 303

Group type: COMPARATOR
Intervention: Crizotinib 250 mg
Number of subjects: 303
Study: 35678747

Group type: EXPERIMENTAL
Intervention: UCLA Alzheimer's and Dementia Care Program
Number of subjects: 1690
Study: 616178325

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care from clinical pharmacists
Number of subjects: 240

Group type: COMPARATOR
Intervention: Common care from medical staff (Control Group)
Number of subjects: 240
Study: 33293204

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo added to standard care
Number of subjects: 50
Study: 32237984

Group type: EXPERIMENTAL
Intervention: Current CST-CR system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical research support
Number of subjects: 0
Study: 33481455

Group type: EXPERIMENTAL
Intervention: Inpatient physical rehabilitation (4-week hospitalization with physical, occupational, and speech therapy)
Number of subjects: 24
Study: 34904190

Group type: EXPERIMENTAL
Intervention: Ketamine (1-2 mg/kg)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Etomidate (0.2-0.3 mg/kg)
Number of subjects: 801
Study: 34065560

Group type: EXPERIMENTAL
Intervention: Training programme in emotional intelligence and social skills (experimental group, n = 55)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual mentoring activities (control group, n = 57)
Number of subjects: 141
Study: 32102058

Group type: EXPERIMENTAL
Intervention: Hypoxic Exercise Training (HET)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normoxic Exercise Training (NET)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both HET and NET
Number of subjects: 23
Study: 35224222

Group type: EXPERIMENTAL
Intervention: Equine placental extract (220 mg, orally, once daily for 4 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (orally, once daily for 4 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Equine placental extract
Number of subjects: 29
Study: 33190085

Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol Turbuhaler®
Number of subjects: 35
Study: 33466128

Group type: EXPERIMENTAL
Intervention: CO2 artificial pneumothorax (group P)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (group N)
Number of subjects: 24
Study: 32286687

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab emtansine (T-DM1) 3.6 mg/kg intravenously every 3 weeks
Number of subjects: 1486

Group type: COMPARATOR
Intervention: Trastuzumab 6 mg/kg intravenously every 3 weeks
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months
Number of subjects: 1486
Study: 34156610

Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional biventricular pacing (BiV)
Number of subjects: 142
Study: 34523673

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily for 21 days
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo equivalent
Number of subjects: 497
Study: 35012011

Group type: EXPERIMENTAL
Intervention: Supervised therapeutic exercise group (STE-G)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unsupervised exercise group (UE-G)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups received patient therapeutic education
Number of subjects: 80
Study: 32289518

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance and Impact Training (HiRIT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Isometric Axial Compression (IAC)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 93
Study: 35246117

Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative clinics
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care from physicians
Number of subjects: 600
Study: 34922023

Group type: EXPERIMENTAL
Intervention: 8-week supervised aerobic and anaerobic training program (3 times per week, 60-min sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 24
Study: 33166726

Group type: EXPERIMENTAL
Intervention: T-SICIp (threshold-tracking at increasing ISIs from 1 to 7 ms)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: T-SICIs (threshold-tracking at increasing ISIs from 1 to 7 ms)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: A-SICI (conventional amplitude measurements)
Number of subjects: 50

Group type: COMPARATOR
Intervention: T-SICIp and A-SICI
Number of subjects: 50
Study: 32150670

Group type: EXPERIMENTAL
Intervention: Pressure rise time (PRT) during PSV‐VG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pressure rise time (PRT) during SIPPV‐VG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Short PRT (0.08 seconds) during PSV‐VG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Different PRTs in either mode
Number of subjects: 12
Study: 36275695

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP) with standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 0
Study: 33074943

Group type: EXPERIMENTAL
Intervention: Adequacy of anaesthesia group (AoA group) using Entropy for depth of hypnosis and surgical pleth index for depth of antinociception
Number of subjects: 494

Group type: COMPARATOR
Intervention: Standard monitoring alone (control group)
Number of subjects: 494
Study: 32609465

Group type: EXPERIMENTAL
Intervention: Structured postoperative physiotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard postoperative approach
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 34228889

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (RT) to sites of oligoprogression
Number of subjects: 72

Group type: COMPARATOR
Intervention: Systemic therapy (ST) escalated
Number of subjects: 72

Group type: COMPARATOR
Intervention: Systemic therapy (ST) maintained
Number of subjects: 72

Group type: COMPARATOR
Intervention: Systemic therapy (ST) discontinued
Number of subjects: 72
Study: 32838476

Group type: EXPERIMENTAL
Intervention: Outpatient therapy (higher, rapid class)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Outpatient therapy (higher, moderate class)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Outpatient therapy (middle, stable class)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Outpatient therapy (low, stable class)
Number of subjects: 120
Study: 35821572

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 58

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 58
Study: 33526043

Group type: EXPERIMENTAL
Intervention: tDCS + walking
Number of subjects: 25

Group type: COMPARATOR
Intervention: tDCS + seated
Number of subjects: 25

Group type: COMPARATOR
Intervention: sham + walking
Number of subjects: 25
Study: 32125080

Group type: EXPERIMENTAL
Intervention: Self-management program (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 33220395

Group type: EXPERIMENTAL
Intervention: E + RT (oral erlotinib 150 mg/d for 2 years or until disease progression or intolerable toxicity and RT 200 cGy/d, 5 d/wk for 6 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: EP + RT (etoposide 50 mg/m2 intravenously on days 1‐5 and 29‐33; cisplatin 50 mg/m2 intravenously on days 1, 8, 29 and 36; and RT as for E + RT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E + RT
Number of subjects: 20

Group type: COMPARATOR
Intervention: EP + RT
Number of subjects: 20
Study: 32550915

Group type: EXPERIMENTAL
Intervention: SC144 (gp130 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SC144
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciclopirox olamine (CPX)
Number of subjects: 0
Study: 33211154

Group type: EXPERIMENTAL
Intervention: Endurance Exercise (EE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 24
Study: 32058426

Group type: EXPERIMENTAL
Intervention: Cariprazine low-dose (0.25-0.5 mg/day)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Cariprazine high-dose (1.5-3.0 mg/day)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 35210111

Group type: EXPERIMENTAL
Intervention: Biodegradable gel containing hyaluronic acid and berberine hydrochloride
Number of subjects: 66

Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 66
Study: 33685502

Group type: EXPERIMENTAL
Intervention: Favipiravir + Lopinavir/ritonavir
Number of subjects: 240

Group type: COMPARATOR
Intervention: Favipiravir + Lopinavir/ritonavir placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Favipiravir placebo + Lopinavir/ritonavir
Number of subjects: 240

Group type: COMPARATOR
Intervention: Favipiravir placebo + Lopinavir/ritonavir placebo
Number of subjects: 240
Study: 32133745

Group type: EXPERIMENTAL
Intervention: rAAV-IL10
Number of subjects: 12

Group type: COMPARATOR
Intervention: Phosphate buffered saline (vehicle)
Number of subjects: 12
Study: 36343582

Group type: EXPERIMENTAL
Intervention: tDCS over the dmPFC
Number of subjects: 70

Group type: COMPARATOR
Intervention: tDCS over the primary visual cortex
Number of subjects: 70
Study: 34552104

Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 19
Study: 34929031

Group type: COMPARATOR
Intervention: Standard cessation advice and NRT (Group A)
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Quit or substitute advice and NRT (Group B)
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Quit or substitute advice and NRT and/or e‐cigarettes (Group C)
Number of subjects: 1563
Study: 33246499

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (2 units of 200 to 250 mL within 12 hours after randomization, with a second administration of 2 units 24 to 36 hours after the first administration)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 483
Study: 35012326

Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg i.v. over 40 minutes) plus psychological therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg i.v. over 40 minutes) plus alcohol education
Number of subjects: 96

Group type: COMPARATOR
Intervention: Saline plus psychological therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Saline plus alcohol education
Number of subjects: 96
Study: 33637568

Group type: EXPERIMENTAL
Intervention: Invasive management (performed in 52% of trial patients)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Registry management (performed in 49% of registry patients)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Invasive management (performed in 32% of trial patients)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Registry management (performed in 36% of registry patients)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Registry patients
Number of subjects: 133
Study: 34330094

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRS (for neurosurgeons)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRS (for radiation oncologists)
Number of subjects: 0
Study: 33823966

Group type: EXPERIMENTAL
Intervention: Drug-associated cue exposure in abstinent MUD group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Scrambled trials (no drug-associated cues) in abstinent MUD group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reaction times in drug cue exposure trials
Number of subjects: 100
Study: 36143964

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCQ + IFNγ
Number of subjects: 0

Group type: COMPARATOR
Intervention: Media alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFNγ (atherogenic cytokine)
Number of subjects: 0
Study: 33373550

Group type: EXPERIMENTAL
Intervention: Access to medical emergency dataset (MED) during handover process
Number of subjects: 72

Group type: COMPARATOR
Intervention: No access to medical emergency dataset (MED) during handover process
Number of subjects: 72
Study: 34230016

Group type: EXPERIMENTAL
Intervention: Subsidy program and standard care
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Usual antenatal care
Number of subjects: 3000
Study: 35913001

Group type: EXPERIMENTAL
Intervention: Multidisciplinary nurse-led community intervention
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 199
Study: 33355689

Group type: EXPERIMENTAL
Intervention: Baobab fruit pulp (BFP) drink for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Isoenergy drink without BFP for 12 weeks
Number of subjects: 58
Study: 32253789

Group type: EXPERIMENTAL
Intervention: Coronary artery surgery plus medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study: 35672893

Group type: EXPERIMENTAL
Intervention: TAC+ETV
Number of subjects: 31

Group type: COMPARATOR
Intervention: ETV
Number of subjects: 31
Study: 34592191

Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study: 35166140

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 34115380

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab (675 mg)
Number of subjects: 2823

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab (675 mg for CM, 225 mg for EM)
Number of subjects: 2823

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2823
Study: 32788567

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35856155

Group type: EXPERIMENTAL
Intervention: High psychological resilience (most resilient BRS group)
Number of subjects: 210